Anesthetics Global Market Report 2022: A $12.24 Billion Market in 2026 – Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Anesthetics Global Market Report 2022, Type, Application, Route of Administration, Local Anesthetics, General Anesthetics” report has been added to ResearchAndMarkets.com’s offering. The global anesthetics market is expected to grow from $9.24 billion in 2021 to $9.88 billion in 2022 at a compound annual growth rate (CAGR) of 7.0 %. The market is expected … [Read more…]

Global Anesthesia and Respiratory Devices Market Report 2022: Market is Expected to Grow to $82.25 Billion in 2026 at a CAGR of 12.4% – Forecast to 2031 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Anesthesia And Respiratory Devices Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. The global anesthesia and respiratory devices market is expected to grow from $45.25 billion in 2021 to $51.51 billion in 2022 at a compound annual growth rate (CAGR) of 13.8%. The market is expected to grow to $82.25 … [Read more…]

Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents

Addition of Aalto Bio Reagents expands Biosynth Carbosynth’s offer to its clinical diagnostics customers. STAAD, Switzerland–(BUSINESS WIRE)–Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry … [Read more…]

CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

CARVYKTI® is Legend Biotech’s first European Commission-approved product The approval is based on the pivotal phase 1b/2 CARTITUDE-1 study, which demonstrated an overall response rate (ORR) of 98 percent in patients with relapsed or refractory multiple myeloma following a one-time treatment with ciltacabtagene autoleucel SOMERSET, N.J.–(BUSINESS WIRE)–$LEGN–Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global … [Read more…]

Health and Social Care Northern Ireland Secures Specialist Support for Largest Ever Digital Transformation Programme

SEATTLE–(BUSINESS WIRE)–#EHR—Health and Social Care Northern Ireland (HSCNI) has enlisted the support of global healthcare technology specialist, Tegria, and digital health consultancy, Cloud21, in a deal to support its national digital transformation programme. The organisations will help to deliver Northern Ireland’s Encompass programme – a decade long initiative that aims to deliver improvements to outcomes … [Read more…]

European Commission Grants Conditional Approval of CARVYKTI® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients who responded experienced a stringent complete response1 BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional … [Read more…]

CORRECTING and REPLACING CAPTION BSI Wins Best Biotech Startup Business of the Year 2022 Award

DAVIS, Calif.–(BUSINESS WIRE)–Please replace the caption with the accompanying correct caption. The release reads: BSI WINS BEST BIOTECH STARTUP BUSINESS OF THE YEAR 2022 AWARD Botanical Solution Inc. (BSI), innovator of sustainable, consistent and cost-effective Advanced Botanical Materials (ABM) for agricultural and pharmaceutical applications, has won the “Best Biotech Startup Business of the Year 2022” … [Read more…]

Microba Life Sciences Signs Partnership With Nib-Backed Midnight Health

Partnership agreement signed with Midnight Health to deliver a world-first personalised consumer health service called Vidality Midnight Health will promote, market and sell a new subscription consumer health service driven by Microba’s core technology nib-backed (ASX: NHF) Midnight Health is a fast growth, Australian-based, digital healthcare company BRISBANE, Australia–(BUSINESS WIRE)–$MAP—Microba Life Sciences Limited (ASX: MAP) … [Read more…]

InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969) announced today that it has received approval to conduct a single-arm, open-label, multicenter phase II clinical trial evaluating the safety and efficacy of tafasitamab in combination with lenalidomide by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) … [Read more…]

Magellan Health Opens 24-hour Crisis Line for Individuals Impacted by the Elementary School Shooting in Uvalde, Texas

Consultation and resources available at no cost to Superior HealthPlan members and local community FRISCO, Texas–(BUSINESS WIRE)–Magellan Health, Inc. today announced that it has opened a complimentary 24-hour crisis line for individuals impacted by the elementary school shooting that occurred in Uvalde, Texas on Tuesday. The line is available to all Superior HealthPlan members and … [Read more…]